Identification of prognostic biomarkers for glioblastomas using protein expression profiling

International Journal of Oncology

Volumn 40, Issue 4, 2012, Pages 1122-1132

  Jung, Yong ^a   Joo, Kyeung Min ^a,b   Seong, Dong Ho ^a,c   Choi, Yoon La ^a   Kong, Doo Sik ^a   Kim, Yonghyun ^a   Kim, Mi Hyun ^a   Jin, Juyoun ^a   Suh, Yeon Lim ^a   Seol, Ho Jun ^a   Shin, Chul Soo ^c   Lee, Jung Il ^a   Kim, Jong Hyun ^a   Song, Sang Yong ^c,d   Nam, Do Hyun ^a  

^a Samsung Medical Center   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Yonsei University   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Automated image analysis; Bioinformatics; Biomarker; Glioblastoma; Therapeutic target; Tissue microarray

Indexed keywords

CDC25B PROTEIN; CYCLIN E; DCC PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; HISTONE H1; PROTEIN; PROTEIN P16; SURVIVIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TISSUE MICROARRAY;

BRAIN NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863337586     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1302     Document Type: Article

References (45)

1. Louis DN: A molecular genetic model of astrocytoma histopathology. Brain Pathol 7: 755-764, 1997.
2. Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helen PT, Schraml P, Kallioniemi OP and Kononen J: Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 60: 6617-6622, 2000.
3. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068, 2008.
4. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE and Kinzler KW: An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812, 2008.
5. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G and Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847, 1998. (Pubitemid 28331029)
6. Kallioniemi OP, Wagner U, Kononen J and Sauter G: Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 10: 657-662, 2001. (Pubitemid 32331572)
7. Fuller CE, Wang H, Zhang W, Fuller GN and Perry A: High-throughput molecular profiling of high-grade astrocytomas: the utility of fluorescence in situ hybridization on tissue microarrays (TMA-FISH). J Neuropathol Exp Neurol 61: 1078-1084, 2002. (Pubitemid 35435026)
8. Lusis EA, Chicoine MR and Perry A: High throughput screening of meningioma biomarkers using a tissue microarray. J Neurooncol 73: 219-223, 2005. (Pubitemid 40974017)
9. Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F, Golanov A, Joos S and Lichter P: Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 64: 3103-3111, 2004. (Pubitemid 38581410)
10. Tynninen O, Carpen O, Jaaskelainen J, Paavonen T and Paetau A: Ezrin expression in tissue microarray of primary and recurrent gliomas. Neuropathol Appl Neurobiol 30: 472-477, 2004. (Pubitemid 39423034)
11. Turbin DA, Leung S, Cheang MC, Kennecke HA, Montgomery KD, McKinney S, Treaba DO, Boyd N, Goldstein LC, Badve S, Gown AM, van de Rijn M, Nielsen TO, Gilks CB and Huntsman DG: Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Res Treat 110: 417-426, 2008. (Pubitemid 351962583)
12. McCarty KS Jr, Miller LS, Cox EB, Konrath J and McCarty KS Sr: Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109: 716-721, 1985. (Pubitemid 16237466)
13. Rexhepaj E, Brennan DJ, Holloway P, Kay EW, McCann AH, Landberg G, Duffy MJ, Jirstrom K and Gallagher WM: Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Res 10: R89, 2008.
14. Kong DS, Song SY, Kim DH, Joo KM, Yoo JS, Koh JS, Dong SM, Suh YL, Lee JI, Park K, Kim JH and Nam DH: Prognostic significance of c-Met expression in glioblastomas. Cancer 115: 140-148, 2008.
15. Sharangpani GM, Joshi AS, Porter K, Deshpande AS, Keyhani S, Naik GA, Gholap AS and Barsky SH: Semi-automated imaging system to quantitate estrogen and progesterone receptor immunoreactivity in human breast cancer. J Microsc 226: 244-255, 2007. (Pubitemid 47024246)
16. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW and Ellis IO: High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116: 340-350, 2005. (Pubitemid 40993329)
17. Abdou AG, Hammam MA, Farargy SE, Farag AG, El Shafey EN, Farouk S and Elnaidany NF: Diagnostic and prognostic role of galectin 3 expression in cutaneous melanoma. Am J Dermatopathol 32: 809-814, 2010.
18. Chen L, Di D, Luo G, Zheng L, Tan Y, Zhang X and Xu N: Immunochemical staining of MT2-MMP correlates positively to angiogenesis of human esophageal cancer. Anticancer Res 30: 4363-4368, 2010.
19. Torlakovic EE, Bilalovic N, Nesland JM, Torlakovic G and Florenes VA: Ets-1 transcription factor is widely expressed in benign and malignant melanocytes and its expression has no significant association with prognosis. Mod Pathol 17: 1400-1406, 2004. (Pubitemid 39472996)
20. Bhargava R, Dabbs DJ, Beriwal S, Yildiz IA, Badve P, Soran A, Johnson RR, Brufsky AM, Lembersky BC, McGuire KP and Ahrendt GM: Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer. Mod Pathol 24: 367-374, 2010.
21. Bolstad BM, Irizarry RA, Astrand M and Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193, 2003. (Pubitemid 36181903)
22. Ihaka R and Gentleman R: A language for data analysis and graphics. J Comp Graph Stat 5: 299-314, 1996.
23. Benjamini Y, Drai D, Elmer G, Kafkafi N and Golani I: Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125: 279-284, 2001. (Pubitemid 33000466)
24. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG and Aldape K: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173, 2006. (Pubitemid 43357943)
25. Jung Y, Seo HJ, Park YR, Kim JH, Bien SJ and Kim JH: Standard-based integration of heterogeneous large-scale DNA microarray data for improving reusability. Genomics and Informatics 9: 19-27, 2011.
26. Mi H, Lazareva-Ulitsky B, Loo R, Kejariwal A, Vandergriff J, Rabkin S, Guo N, Muruganujan A, Doremieux O, Campbell MJ, Kitano H and Thomas PD: The PANTHER database of protein families, subfamilies, functions and pathways. Nucleic Acids Res 33: D284-D288, 2005. (Pubitemid 40207879)
27. Gurzov EN and Izquierdo M: Cyclin E1 knockdown induces apoptosis in cancer cells. Neurol Res 28: 493-499, 2006. (Pubitemid 44141316)
28. Kleinschmidt-DeMasters BK, Heinz D, McCarthy PJ, Bobak JB, Lillehei KO, Shroyer AL and Shroyer KR: Survivin in glioblastomas. Protein and messenger RNA expression and comparison with telomerase levels. Arch Pathol Lab Med 127: 826-833, 2003. (Pubitemid 36792309)
29. Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J, Adelaide J, Koki A, Houvenaeghel G, Hassoun J, Maraninchi D, Viens P, Birnbaum D and Bertucci F: Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 65: 767-779, 2005. (Pubitemid 40216434)
30. Ikota H, Kinjo S, Yokoo H and Nakazato Y: Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology. Acta Neuropathol 111: 475-482, 2006.
31. Shirai K, Suzuki Y, Oka K, Noda SE, Katoh H, Itoh J, Itoh H, Ishiuchi S, Sakurai H, Hasegawa M and Nakano T: Nuclear survivin expression predicts poorer prognosis in glioblastoma. J Neurooncol 91: 353-358, 2009.
32. Mita AC, Mita MM, Nawrocki ST and Giles FJ: Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14: 5000-5005, 2008.
33. Reus K, Mayer J, Sauter M, Zischler H, Muller-Lantzsch N and Meese E: HERV-K(OLD): ancestor sequences of the human endogenous retrovirus family HERV-K(HML-2). J Virol 75: 8917-8926, 2001. (Pubitemid 32851896)
34. Sauter J, and Kopp KH: (The effects of high altitude on the cardiovascular system). Anasthesiol Intensivmed Notfallmed Schmerzther 36: 299-301, 2001.
35. Lei Y, Geng Z, Guo-Jun W, He W and Jian-Lin Y: Prognostic significance of survivin expression in renal cell cancer and its correlation with radioresistance. Mol Cell Biochem 344: 23-31, 2010.
36. Sutherland RL and Musgrove EA: Cyclin E and prognosis in patients with breast cancer. N Engl J Med 347: 1546-1547, 2002. (Pubitemid 35315834)
37. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G Jr, Jessup JM, Loda M and Summerhayes IC: The DCC protein and prognosis in colorectal cancer. N Engl J Med 335: 1727-1732, 1996. (Pubitemid 26399347)
38. Ghellal A, Li C, Hayes M, Byrne G, Bundred N and Kumar S: Prognostic significance of TGF beta 1 and TGF beta 3 in human breast carcinoma. Anticancer Res 20: 4413-4418, 2000. (Pubitemid 32141796)
39. Hama T, Yuza Y, Saito Y, O-uchi J, Kondo S, Okabe M, Yamada H, Kato T, Moriyama H, Kurihara S and Urashima M: Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist 14: 900-908, 2009.
40. Geisler SA, Olshan AF, Weissler MC, Cai J, Funkhouser WK, Smith J and Vick K: p16 and p53 protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res 8: 3445-3453, 2002. (Pubitemid 35340720)
41. Zhao P, Hu YC and Talbot IC: Expressing patterns of p16 and CDK4 correlated to prognosis in colorectal carcinoma. World J Gastroenterol 9: 2202-2206, 2003. (Pubitemid 37321445)
42. Boldrini L, Gisfredi S, Ursino S, Lucchi M, Mussi A and Fontanini G: CDC25B: relationship with angiogenesis and prognosis in non-small cell lung carcinoma. Hum Pathol 38: 1563-1568, 2007. (Pubitemid 47418968)
43. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S and Wen PY: Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70: 779-787, 2008.
44. Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton RF, Rowland KM Jr, Mischel P, Yong WH, Scheithauer BW, Schiff D, Giannini C and Buckner JC: North Central Cancer Treatment Group Study N0177: Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 26: 5603-5609, 2008.
45. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM and Hayes DN: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110, 2010.